Since the PI3K/AKT/mTOR pathway has a high mutation rate in endometrial cancer and all of them are kinases, targeting the three major molecules of this pathway, PI3K/AKT/mTOR, has become a hot research topic for the treatment of endometrial cancer in recent years. Here, AKT1 is linked to endometrial cancer.